Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 379

Document Document Title
WO/2022/153266A1
This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.  
WO/2022/133604A1
Methods using 2-Bromo-LSD or a derivative or salt thereof to treat subjects suffering from mental and/or mood disorders. The 2-Bromo-LSD is provided as a pharmaceutical composition formulated in a variety of manners for resolving symptom...  
WO/2022/129437A1
The present application relates to long Stokes shift chromenoquinoline dyes and their uses as fluorescent labels. For example, these dyes may be used to label nucleotides for nucleic acid sequencing applications. The chromenoquinoline dy...  
WO/2022/107095A1
Disclosed are methods of treating pain, such as headaches, comprising administering an ergotamine and thymoquinone, wherein the ergotamine is selected from the group consisting of BOL-148, lysergic acid diethylamide (LSD), and lysergic a...  
WO/2022/023813A1
Disclosed herein are methods of treating neuropsychiatric and cognitive diseases, disorders, or conditions, such as social disfunction, with repeated doses of a modulator of the AMPA receptor and/or the 5-HT2A receptor.  
WO/2022/008627A2
The present invention provides an improved method for the production of lysergic acid diethylamide (LSD) for GMP purposes. Furthermore, the present invention provides novel LSD derivatives of formula (I) as well as their synthesis and pu...  
WO/2021/243461A1
Disclosed is a method of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication thereof, and/or altering the diet of an individual comprising administering DMT, LSD, LSA, or an analog thereof.  
WO/2021/209815A1
The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethyl amine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention a...  
WO/2021/081634A1
A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acety...  
WO/2020/123607A1
Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches. The present disclosure provides new methods of medical treatment or prevention (e.g, f...  
WO/2019/246532A1
The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro p...  
WO/2019/083892A1
Embodiments of the present invention provide materials and methods for preventing and treating ergot-based toxicity in animals, including humans. In particular, the present disclosure provides materials and methods for ameliorating the h...  
WO/2018/223065A1
The present invention provides novel neuromodulatory compounds and compositions thereof. The invention also relates to methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for p...  
WO/2018/076019A1
A novel quantum-based computational process for drug discovery and design was used to identify potential novel liver-stage anti-malarial therapeutic molecules. The approach combined the latest big-data advances in high-throughput bioassa...  
WO/2017/184875A1
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyper...  
WO/2016/118541A1
Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...  
WO/2015/051307A1
Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a β-elimination mechanism.  
WO/2014/114664A1
The present invention relates to a process for producing 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) including salts and hydrates thereof of general formula (I) from the respective cyclen. Said process further i...  
WO/2014/100354A1
Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migr...  
WO/2014/078857A1
The invention provides compounds of formula (I) wherein R1-R4 have any of the values defined in the specification, and salts thereof. The compounds are useful as dopamine receptor modulators for the treatment of diseases where modulation...  
WO/2012/177962A1
Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...  
WO/2012/001308A9
The present invention relates to a method for preparing structural analogues of tetracyclic, pentacyclic, and polycyclic ergoline alkaloids, in four steps, from an indole-3-carboxaldehyde, wherein the method includes the following two ke...  
WO/2011/059463A1
This invention relates to deuterated indolocarbazole compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.  
WO/2010/045527A1
The present invention is directed to methods and kits for the determining the presence or absence of ergot alkaloids in sample which use chromatographic instrumentation and columns operating at a pressure of 4,000 to 15,000 psi and colum...  
WO/2010/000676A1
The present invention relates to a method for preparing microbiologically produced ergot alkaloids of the following formula (I), comprising the step of: a) extracting the fermentation product occurring during the biological production, s...  
WO/2009/133097A1
A process for producing N-6 demethylated 9,10-dihydrolysergic acid alkyl ester is described, which comprises a step of N-6 demethylation of 9,10-dihydrolysergic acid alkyl esters with chloroformate and wherein the N-6 demethylation step ...  
WO/2009/071607A2
The present invention relates to new Ergot alkaloid derivatives of the general formula (I) or pharmaceutically acceptable salts thereof as well as to the use of specific compounds as selective radical scavengers for neurons.  
WO/2008/104956A2
The present invention relates to processes for the preparation of amorphous cabergoline by agitated thin film drying or spray drying.  
WO/2008/092881A1
The present invention relates to a cabergoline crystal form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and to pharmaceutical compositions containing the new form.  
WO/2008/049884A1
The present invention relates to a process for producing cabergoline crystal forms. The process comprises preparation of the desired solvate of cabergoline from a solution of cabergoline in chloroaromatic solvents. Afterwards cabergoline...  
WO/2008/043601A2
The present invention relates to a transdermal therapeutic system (TTS) comprising an impermeable covering layer, a matrix containing an ergolin compound of formula (I) or the physiologically compatible salt or derivative thereof, wherei...  
WO/2007/091039A2
The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.  
WO/2007/012846A1
A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides...  
WO2006097345A9
The invention relates to a process for preparing cabergoline of formula (1).  
WO/2006/128658A1
Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or - phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C...  
WO/2006/100492A2
A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) or 1,3,5- trimethylbenzene and obtaining cabergoline Form I from the solvate. Another aspect of the...  
WO/2006/053899A1
The invention relates to a cabergoline preparation method comprising the reaction of a derivative having general formula III, wherein R1 represents a secondary amine function protecting group, with ethyl isocyanate in order to obtain a p...  
WO/2005/105796A1
The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed in a method for preparing ca...  
WO/2005/085243A2
A process for preparing cabergoline (I) from ergoline-8β-carboxylic acid ester (XIII) comprising the following steps. (XIII), (XVI), (XVII), (XVIII), (XIX), (I). The present case also relates to the intermediates (XVI), (XVII), (XVIII) ...  
WO/2005/082902A1
Lysergic acid is formed in high yields and high quality by isomerizing paspalic acid in a phase separated mixture formed by paspalic acid and a concentrated aqueous metal hydroxide solution.  
WO2004101510B1
Provided are new crystalline Forms, VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.  
WO/2004/094368A2
The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medica...  
WO/2003/078392A2
A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/heptane or toluene/hexane mixture starting from raw cabergoline, followed by recovery and removal of th...  
WO/2003/078433A1
A process for producing crystalline form I of cabergoline, which process comprises the preparation of Form V using heptane as precipitation solvent, and its exclusive conversion into crystalline Form I of cabergoline. The present crystal...  
WO/2003/078432A2
A process for the synthesis of pergolide (Formula(I)) (D-6-n-propyl-8β­methylmercaptomethylergo line) from acid 9,10-dihydrolysergic is herein disclosed. The process can be carried out without isolating most intermediates and is partic...  
WO/2003/078408A1
Parecoxib sodium is provided in a crystalline form that is substantially anhydrous and substantially nonsolvated. Various such anhydrous, nonsolvated crystal forms have been identified, including Forms A, B and E as described herein. Als...  
WO/2003/076439A2
The invention relates to 1-allyl ergot alkaloids and derivatives thereof, comprising characteristics that are selectively antagonistic towards 5-HT2-receptors, for preventing and alleviating among others, migraine headaches, Parkinson's ...  
WO/2002/100888A1
Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is : 6-n-propyl-8$g(b)-ergolinglmethylthioacetyl-D-Phe-c-(Cys-Tyr -D-Trp-Lys-Abu-Cys)-Thr-NH¿2?  
WO/2002/085902A1
A process for preparation of $m(f)i$m(g)N$m(f)/i$m(g)-(ergoline-8$g(b)-carbonyl)ureas of the formula [I] their stereoisomers as well as acid addition salts thereof which process comprises silylating an ergoline -8$g(b)-carboxamide of the...  
WO/2002/034267A1
The invention relates to the use of a dopamine agonist in the form of an agent, comprising at least two physically separate compositions, of which one is a transdermal therapeutic system (TTS), containing the dopaminergic agent and one o...  

Matches 1 - 50 out of 379